Our ambition for precision medicine in chronic diseases



Published
For decades scientists have studied the causes of disease; the interplay between genes, molecular drivers and the environment. Precision medicines – targeting the right medicine to the right patient at the right time – have revolutionised the treatment of some cancers and rare genetic diseases, yet precision medicines for chronic diseases are far less common.  

The challenge we face is that chronic diseases are biologically complex and driven by multiple mechanisms. It is for this reason that chronic diseases, such as chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) have seen little innovation in decades.

To improve patient outcomes, we must move beyond the current standard of care in which many patients are treated the same (a ‘one-size-fits-all’ approach) and sequentially across the disease pathway, and towards the possibility of targeting treatments to specific and earlier disease states.

This video hears from Precision Medicine leaders at AstraZeneca on how, by unravelling the complex underlying biology, and pioneering and applying advanced technologies, we are collaborating with our partners to lead the way in a new era of precision medicines for chronic diseases; driving for better patient outcomes and a healthier and more sustainable future for patients and healthcare systems. 

https://www.astrazeneca.com/r-d/precision-medicine.html
------------------------------------------------------------
Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/

Follow us:
Twitter: https://twitter.com/AstraZeneca
LinkedIn: https://www.linkedin.com/company/astrazeneca/
Instagram: https://www.instagram.com/astrazeneca/
Facebook: https://www.facebook.com/astrazeneca/
Category
Health
Be the first to comment